RecruitingPhase 2NCT06104618
Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis
Studying Malignant tumor of penis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mayo Clinic
- Principal Investigator
- Lance C. Pagliaro, M.D.Mayo Clinic in Rochester
- Intervention
- Enfortumab Vedotin(drug)
- Enrollment
- 28 enrolled
- Eligibility
- 18 years · MALE
- Timeline
- 2023 – 2026
Study locations (3)
- Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
- Mayo Clinic in Florida, Jacksonville, Florida, United States
- Mayo Clinic in Rochester, Rochester, Minnesota, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06104618 on ClinicalTrials.govOther trials for Malignant tumor of penis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07110038DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile CarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- RECRUITINGPHASE2NCT06353906Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile CancerThe Netherlands Cancer Institute
- ACTIVE NOT RECRUITINGPHASE3NCT06465914A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese MalesShanghai Bovax Biotechnology Co., Ltd.
- ENROLLING BY INVITATIONNCT06565585Prediction of Local Recurrence and Its Impact on Long-term Outcomes After Low-risk Glans-sparing Surgery for Penile Squamous Cell CarcinomaUniversitaire Ziekenhuizen KU Leuven
- RECRUITINGPHASE2NCT06415318TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile CancerSun Yat-sen University
- RECRUITINGPHASE1NCT05999396FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal CancerGerman Cancer Research Center
- RECRUITINGNANCT05899361A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of InterestDana-Farber Cancer Institute
- ACTIVE NOT RECRUITINGNANCT05946993Linking In With Advice and Supports for Men Impacted by Metastatic CancerUniversity College Cork